Everist Genomics is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies which help physicians improve medical outcomes and reduce the total cost of care. EGI's innovative products successfully integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology which until now has been confined to the hospital setting.
Assists physicians in identifying early-stage colorectal cancer patients likely to benefit from adjuvant chemotherapy
Assists physicians in assessing prognosis and defining optimal treatment for colorectal cancer patients
Identifies patients with high life-time risk of developing one of several types of cancer
Assists physicians in determining which type of chemotherapy a colorectal cancer patient is likely to respond best to; 5-FU or irinotecan